Informace o publikaci

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Autoři	PALUMBO A. BRINGHEN S. LUDWIG H. DIMOPOULOS M.A. BLADÉ J. MATEOS M.V. ROSINOL L. BOCCADORO M. CAVO M. LOKHORST H. ZWEEGMAN S. TERPOS E. DAVIES F. DRIESSEN C. GIMSING P. GRAMATZKI M. HÁJEK Roman JOHNSEN H.E. LEAL DA COSTA F. SEZER O. SPENCER A. BEKSAC M. MORGAN G. EINSELE H. SAN MIGUEL J.F. SONNEVELD P.
Rok publikování	2011
Druh	Článek v odborném periodiku
Časopis / Zdroj	Blood
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1182/blood-2011-06-358812
Doi	http://dx.doi.org/10.1182/blood-2011-06-358812
Obor	Onkologie a hematologie
Klíčová slova	multiple myeloma; therapy;Prednisone; Thalidomide; Randomized Controlled-Trial; Hematopoietic-Cell Transplantation; Dexamethasone; Prognostic Index
Popis	Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome.